The p110β isoform-specific PI3K inhibitor TGX-221 and its analogue BL140 have also both shown efficacy in preclinical models of prostate cancer with PTEN loss [175,176,177,178,179], and BL140 is also reported to overcome resistance to enzalutamide in vitro [179]. This evidence concerns the gene PTEN and prostate carcinoma.